Sabra Health Care REIT, Inc. cash flow to debt ratio of 13.67% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Sabra Health Care REIT, Inc.'s free cash flow has increased 12.26% from $310.54M last year to $348.61M, signaling increasing performance

Sabra Health Care REIT, Inc.'s debt to equity ratio is 0.46, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Sabra Health Care REIT, Inc.'s debt has decreased relative to shareholder equity from 0.89 last year to 0.46 today, signaling strengthened financials

Sabra Health Care REIT, Inc. has a net debt to EBITDA ratio of 5.43x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Sabra Health Care REIT, Inc.'s interest coverage ratio is 1.15, which means that the company struggles to meet interest obligations, signaling financial risk.

Sabra Health Care REIT, Inc.'s profit margin has decreased (-57.75%) in the last year from 18.02% to 7.61%, signaling decreasing performance

Sabra Health Care REIT, Inc.'s short-term liabilities of $336.91M exceed its short-term assets of $189.43M, signaling financial risk

Sabra Health Care REIT, Inc.'s return on assets of 1.19% is lower than the 5.00% threshold, indicating inefficient asset utilization

Sabra Health Care REIT, Inc.'s return on equity of 2.34%, is lower than 15.00%, indicating bad performance

Sabra Health Care REIT, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Sabra Health Care REIT, Inc. had positive net income in 3.00 out of 5 years, indicating stable and consistent earnings

Sabra Health Care REIT, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Sabra Health Care REIT, Inc. has a free cash flow yield of 6.80%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Sabra Health Care REIT, Inc.'s yearly earnings has increased 22.81% since last year from $126.71M to $155.61M, signaling increasing performance

Sabra Health Care REIT, Inc.'s yearly revenue has increased 10.15% since last year from $703.24M to $774.63M, signaling increasing performance

ROIC 22.89% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Sabra Health Care REIT, Inc.'s 3-year revenue CAGR of 7.43% is positive, indicating growing revenue over the past 3 years

Sabra Health Care REIT, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Sabra Health Care REIT, Inc. had positive ROE in 3.00 out of 5 years, indicating consistent and reliable returns on equity

Sabra Health Care REIT, Inc. is overvalued relative to its fair value price of 11.84 based on Discounted Cash Flow model

Sabra Health Care REIT, Inc. has an earnings yield of 1.28%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Sabra Health Care REIT, Inc. is overvalued relative to its fair value price of 2.86 based on EBITDA multiple model

Sabra Health Care REIT, Inc. has an EV/EBITDA ratio of 16.64x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Sabra Health Care REIT, Inc. is undervalued relative to its fair value price of 21.95 based on Earnings Fair Value model

Sabra Health Care REIT, Inc. has no meaningful EPS growth rate; PEG ratio cannot be computed.

Sabra Health Care REIT, Inc. has a price-to-book ratio of 1.86x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Sabra Health Care REIT, Inc. has a price-to-sales ratio of 5.96x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue